UCLA research shows why immune checkpoint blockade impedes but does not stop glioblastoma progression
University of California, Los Angeles (UCLA), Health SciencesLike locking the door but opening windows, an immune checkpoint therapy temporarily slows glioblastoma progression but fails to establish an effective anti-tumor microenvironment and appears to increase molecular interactions inhibiting long-term immune response.